ERN-EuroBloodNet member Vall d'Hebron Barcelona Hospital Campus will become the new headquarters and coordinator of the International Conference of Rare Diseases and Orphan Drugs (ICORD) from January 2019 following the unanimous decision undertaken on the ICORD General Assembly for members held in Stockholm last September. ICORD will be leaded by Dr. Joan X. Comella, director of the Vall d'Hebron Research Institute (VHIR) and Dr. Manuel Posada, director of the Research Institute for Rare Diseases (IIER) at the Institute of Health Carlos III (ISCIII). At this assembly, Vall d'Hebron was represented by Dr. Guillem Pintos, as clinical director of Rare Diseases.
ICORD is an International Society for all individuals actively involved in rare diseases and/or orphan drugs with the aim to improve the welfare of patients with rare diseases and their families world-wide through better knowledge, research, care, information, education and awareness. Since its founding in 2007, ICORD has been coordinated by, also the ERN-EuroBloodNet member, Karolinska Institute in Stockholm.
Vall d'Hebron already counts with nearly 100 specialists dedicated to the care of more than 300 rare diseases, being not only the most important hospital dealing with rare diseases at the national level, but also one of the leading hospitals in Europe for this field, also supported through its participation in 10 different European Reference Networks (ERNs).
Vall d'Hebron is represented at the Board of ERN-EuroBloodNet by Cristina Diaz de Heredia and David Beneitez Pastor. In addition, Maria del Mar Mañú Pereira, ERN-EuroBloodNet Scientific Director, and Victoria Gutiérrez Valle, ERN-EuroBloodNet IT and dissemination manager, both from ERN-EuroBloodNet coordination team, are based at Vall d'Hebron Barcelona Hospital Campus through a collaboration agreement with the coordinating center of the network.